RT @FranciscoMarty_: #Dexamethasone in Hospitalized Patients with #Covid19 https://t.co/LTzlFEw48f #RecoveryTrial out after peer review…
RT @PeterHorby: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report now published @NEJM #recoverytrial https://t.co/T…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
Lo leímos antes en todos lados, pero el uso de dexametasona en pacientes hospitalizados parece reducir la mortalidad en oacie tés con #COVID19 HOSPITALIZADOS 🏨🏥 Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM https://t.co
RT @wszczeklik: WYNIKI badania RECOVERY ukazały się dzisiaj w NEJM! 6mg deksametazonu przez 10 dni powinni dostawać wszyscy pacjenci z #COV…
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM Now peer reviewed #COVID19 https://t.co/dUuZ9nl9hy
RT @FranciscoMarty_: #Dexamethasone in Hospitalized Patients with #Covid19 https://t.co/LTzlFEw48f #RecoveryTrial out after peer review…
RT @wszczeklik: WYNIKI badania RECOVERY ukazały się dzisiaj w NEJM! 6mg deksametazonu przez 10 dni powinni dostawać wszyscy pacjenci z #COV…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
Reducción de mortalidad en Pacientes hospitalizados con #COVID19 que reciben oxígeno o que tienen ventilación mecánica usando #dexametasona. Resultados preliminares de hoy del estudio RECOVERY. Gana peso esta intervención. https://t.co/KVEE8smAIn https://t
RT @PeterHorby: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report now published @NEJM #recoverytrial https://t.co/T…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM Next results from RECOVERY out now. https://t.co/lLqd35RPRO
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
RT @GermHunterMD: 🔥 #RECOVERYtrial study of dexamethasone in hospitalized patients with Covid19 now peer reviewed and published @NEJM See…
RT @GermHunterMD: 🔥 #RECOVERYtrial study of dexamethasone in hospitalized patients with Covid19 now peer reviewed and published @NEJM See…
RT @FranciscoMarty_: #Dexamethasone in Hospitalized Patients with #Covid19 https://t.co/LTzlFEw48f #RecoveryTrial out after peer review…
イギリスで先月概要公表された大規模研究で重症COVID19へのデキサメサゾン(DEX)の効果を示す論文がニューイングランド・ジャーナル・オブ・メディスン誌掲載。人工呼吸装着例の28日時点死亡率がDEX投与群29.3%、対象群41.4%で有意に約35%低下。酸素非投与例では死亡率上昇。 https://t.co/CyYVby0S3E
RT @analise_covid19: Ensaio clínico controlado e randomizado da Recovery mostrando que a Dexametasona reduziu a mortalidade em 28 dias em p…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
With huge thanks to the team @Oxford_NDPH, all our collaborators around the UK and above all the participants, we give you our first peer-reviewed paper. #recoverytrial @PeterHorby @MartinLandray @EdJuszczak https://t.co/MNaSaFD8lV
RT @josegallucci: Recovery trial mostrando os efeitos da dexametasona saiu do preprint hoje para o @NEJM. Dexamethasone in Hospitalized Pat…
RT @GermHunterMD: 🔥 #RECOVERYtrial study of dexamethasone in hospitalized patients with Covid19 now peer reviewed and published @NEJM See…
WYNIKI badania RECOVERY ukazały się dzisiaj w NEJM! 6mg deksametazonu przez 10 dni powinni dostawać wszyscy pacjenci z #COVID__19, którzy potrzebują tlenoterapii. Leczenie (kortykoterapia) zmniejsza śmiertelność o 17% (RR 0.83 95%CI 0.75-0.93). https://t.c
RT @PerlasClinicas: Ha sido publicado formalmente en su versión definitiva el esperado estudio de dexametasona en COVID19 (brazo de tratami…
RT @FranciscoMarty_: #Dexamethasone in Hospitalized Patients with #Covid19 https://t.co/LTzlFEw48f #RecoveryTrial out after peer review…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
RT @PeterHorby: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report now published @NEJM #recoverytrial https://t.co/T…
RT @GermHunterMD: 🔥 #RECOVERYtrial study of dexamethasone in hospitalized patients with Covid19 now peer reviewed and published @NEJM See…
RT @CarlosdelRio7: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | The Recovery dexamethasone study is now publ…
RT @GermHunterMD: 🔥 #RECOVERYtrial study of dexamethasone in hospitalized patients with Covid19 now peer reviewed and published @NEJM See…
RT @FranciscoMarty_: #Dexamethasone in Hospitalized Patients with #Covid19 https://t.co/LTzlFEw48f #RecoveryTrial out after peer review…
RT @rkwadhera: RECOVERY Trial now published in @NEJM Dexmethasone reduces death within 28 days in #COVID19 patients receiving oxygen or me…
artigo sobre braço da dexametasona do estudo randomizado Recovery publicado no New England Journal of Medicine. dexametasona em pacientes com covid em suporte respiratório salvou vidas! enquanto isso, perdemos tempo, dinheiro e energia falando de medic
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
Decadron worx
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
Prelim of the RECOVERY trial: besides the fact that pt on IMV or oxygen did better The subgroup analysis of patients without oxygen seemed to do worse https://t.co/2gfm3M8ax8
RT @PeterHorby: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report now published @NEJM #recoverytrial https://t.co/T…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
RT @PerlasClinicas: Ha sido publicado formalmente en su versión definitiva el esperado estudio de dexametasona en COVID19 (brazo de tratami…
Ha sido publicado formalmente en su versión definitiva el esperado estudio de dexametasona en COVID19 (brazo de tratamiento del estudio Recovery). Les comparto el enlace: https://t.co/HigoQuGNVz
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
The use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. #COVID19 https://t.co/oglu4hqTaq
RT @MartinLandray: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM https://t.co/wKkAmAc91X
RT @FranciscoMarty_: #Dexamethasone in Hospitalized Patients with #Covid19 https://t.co/LTzlFEw48f #RecoveryTrial out after peer review…
Ensaio clínico controlado e randomizado da Recovery mostrando que a Dexametasona reduziu a mortalidade em 28 dias em pacientes com COVID-19 hospitaliados RECEBENDO ventilaão ou suporte de oxigênio, MAS NÃO naqueles que nao receberam suporte respiratório
RT @PeterHorby: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report now published @NEJM #recoverytrial https://t.co/T…
RT @CarlosdelRio7: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | The Recovery dexamethasone study is now publ…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
RT @rkwadhera: RECOVERY Trial now published in @NEJM Dexmethasone reduces death within 28 days in #COVID19 patients receiving oxygen or me…
RECOVERY trial Dexa paper in full . The accompanying editorial by Dr Fouci . Remarkable effort by #NHS @NIHRresearch networks https://t.co/eqBTxUZeLm
#Dexamethasone in Hospitalized Patients with #Covid19 https://t.co/LTzlFEw48f #RecoveryTrial out after peer review Time to read. Further thoughts later. https://t.co/0psjLqYJde
RT @GermHunterMD: 🔥 #RECOVERYtrial study of dexamethasone in hospitalized patients with Covid19 now peer reviewed and published @NEJM See…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
RT @CarlosdelRio7: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | The Recovery dexamethasone study is now publ…
RT @GermHunterMD: 🔥 #RECOVERYtrial study of dexamethasone in hospitalized patients with Covid19 now peer reviewed and published @NEJM See…
RT @CarlosdelRio7: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | The Recovery dexamethasone study is now publ…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
Dexamethasone (6mg/j) dans la COVID-19 pour les patients sous respirateur ou sous oxygène. Étude Recovery https://t.co/TnASZAy7oY
デキサメタゾン、コロナ重症者に効果♡有り
RT @GermHunterMD: 🔥 #RECOVERYtrial study of dexamethasone in hospitalized patients with Covid19 now peer reviewed and published @NEJM See…
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM https://t.co/t4I82DSA2u #MedTwitter #IDtwitter. Data shows significant improvement in patients receiving ventilatory/respiratory support. No significant benefit in less ill
RT @rkwadhera: RECOVERY Trial now published in @NEJM Dexmethasone reduces death within 28 days in #COVID19 patients receiving oxygen or me…
RT @PeterHorby: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report now published @NEJM #recoverytrial https://t.co/T…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
🔥 #RECOVERYtrial study of dexamethasone in hospitalized patients with Covid19 now peer reviewed and published @NEJM See recent #IDJClub for how #IDTwitter interpreted this landmark study. On first glance, results look just as good. https://t.co/OedE4Nt5
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
RT @josegallucci: Recovery trial mostrando os efeitos da dexametasona saiu do preprint hoje para o @NEJM. Dexamethasone in Hospitalized Pat…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
Recovery trial mostrando os efeitos da dexametasona saiu do preprint hoje para o @NEJM. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM https://t.co/x2ftNaMBmM
it’s out today: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM https://t.co/BOlYQA3S28
RT @grahamscooke: Dexamethasone data from Recovery trial now published @nejm in double quick time https://t.co/R2mh6U8bKb. Only minor diff…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
RT @MinervaCardioa1: Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report, by the RECOVERY Collaborative Group https:/…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
RT @ogi_gajic: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM https://t.co/0flbX1Flj6
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM https://t.co/0flbX1Flj6
Dexametasona en pacientes hospitalizados con Covid-19 Paper en "The New England Journal of Medicine". https://t.co/EKuFgCtnQY
RT @CarlosdelRio7: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | The Recovery dexamethasone study is now publ…
RT @PeterHorby: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report now published @NEJM #recoverytrial https://t.co/T…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM https://t.co/7Gc0CR3V2b
RECOVERY Trial now published in @NEJM Dexmethasone reduces death within 28 days in #COVID19 patients receiving oxygen or mechanical ventilation. No benefit in those not requiring respiratory support. https://t.co/lunUcDz63Y https://t.co/3VuqdPS9G0
Dexamethasone data from Recovery trial now published @nejm in double quick time https://t.co/R2mh6U8bKb. Only minor differences from pre-print
« The use of #dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. » https://t.co/UjdSRZ81kk
RT @CarlosdelRio7: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | The Recovery dexamethasone study is now publ…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
Orage cytokinique = DXM on le sait! cf SALH!! ce n est pas éthique une etude de ce style....desolé on a tous vu de nombreux patients (pas tous) qui s'aggravaient vers J10 bénéficier de la DMX ou autres Cortico. @raoult_didier @philippefroguel
RT @CarlosdelRio7: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | The Recovery dexamethasone study is now publ…
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | The Recovery dexamethasone study is now published in @NEJM A 22.9% mortality in the dexamethasone vs 25.7% in usual care group. https://t.co/k8v1yTtAGm
RT @PeterHorby: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report now published @NEJM #recoverytrial https://t.co/T…
Dexa for covid Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM https://t.co/OKL3o9ppNC https://t.co/w8bZgqhodk
And now to play spot the difference with the preprint... 🧐 #COVID19 #dexamethasone #recoverytrial @NEJM https://t.co/UNR31kGon4
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…
Rapport préliminaire sur l'utilisation de la dexamethasone chez des patients hospitalisés atteints de la #COVIDー19 https://t.co/6or0o3q5FR
RT @EricTopol: The dexamethasone #recoverytrial, showing survival advantage for severe #COVID19, was just published in @NEJM, with an acco…